Antagonisty retseptorov k angiotenzinu II: obzor effektivnosti i bezopasnosti


Cite item

Full Text

About the authors

Yu. N Eremina

ГБОУ ВПО Российский национальный исследовательский университет им. Н.И.Пирогова Минздрава РФ

Кафедра клинической фармакологии

M. V Leonova

ГБОУ ВПО Российский национальный исследовательский университет им. Н.И.Пирогова Минздрава РФ

Кафедра клинической фармакологии

A. A Galitskiy

ГБОУ ВПО Российский национальный исследовательский университет им. Н.И.Пирогова Минздрава РФ

Кафедра клинической фармакологии

References

  1. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7: 1–94.
  2. Nixon R.M., Muller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta - analytical approach. Int J Clin Pract 2009; 63 (5): 766–75.
  3. Neutel J et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997; 19: 447–58.
  4. Sawada T et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks. KYOTO HEART Study Eur Heart J 2009; 30 (20): 2461–9.
  5. Thürmann P.A., Kenedi P, Schmidt A. et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–42.
  6. Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21: 76–86.
  7. Dahlof B, Devereux R.B.., Kristiansson K. et al. LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study: a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
  8. Schmidt and Schmieder. Hypertension and LVH: How much attention should we pay to the RAAS. Dialogues on Cardiovascular Medicine 2005; 10 (1): 36.
  9. Robert H. Fagard, Hilde Celis, Lutgarde Thijs and Stijn Wouters. Regression of left ventricular mass by antihypertensive Tteatment: a meta - analysis of randomized comparative studies. Hypertension 2009; 54: 1084–91.
  10. Wachtell K. et al. Angiotensin II receptor blockade reduces new - onset atrial fibrillation and subsequent stroke cmpared to atenolol. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol 2005; 45: 712–9.
  11. Eijkelkamp W.B., Zhang Z, Remuzzi G. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18 (5): 1540–6.
  12. Burgess E, Bakris G, Weir M, Koval S. Comparative long term effects of two AT 1 receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. J Hypertens 2007; 25 (Suppl. 2): S27.
  13. Haller H, Ito S, Izzo J.L. et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 9907.
  14. Kunz R, Friedrich C, Wolbers M, Mann J.F.E. Meta - analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med 2008; 148: 30–48.
  15. Xie Q.Y., Wang Y.J., Sun Z.L., Yang T.L. Effects of valsartan and indapamide on plasma cytokines in essential hypertension. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006; 31 (5): 629–34.
  16. Manabe S, Okura T, Watanabe S. et al. Effects of angiotensin II receptor blockade with valsartan on pro - inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46 (6): 735–9.
  17. Nakamura T, Fujii S, Hoshino J. et al. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28 (12): 937–43.
  18. Lewington S, Clarke R, Qizilbash N et al. Age - specific relevance of usual blood pressure to vascular mortality: a meta - analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002; 360: 1903–13.
  19. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood - pressure - lowering regimens on major cardiovascular events: results of prospectively - designed overviews of randomised trials. Lancet 2003; 362: 1527–35.
  20. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure - dependent and independent effects of agents that inhibit the renin - angiotensin system. J Hypertens 2007; 25: 951–8.
  21. Julius S, Kjeldsen S.E., Weber M. et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
  22. Yusuf S, Diener H.C., Sacco R.L. et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008; 359 (12): 1225–37.
  23. Bangalore S, Parkar S, Grossman E, Messerli F.H. A meta - analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new - onset diabetes mellitus. Am J Cardiol 2007; 100 (8): 1254–62.
  24. Sipahi I, Debanne S.M., Rowland D.Y. et al. Angiotensin - receptor blockade and risk of cancer: meta - analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627–36.
  25. Coleman C.I., Baker W.L., Kluger J, White C.M. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta - analysis of randomized controlled trials. J Hypertens 2008; 26 (4): 622–9.
  26. Chin H.J., Oh S.W., Goo H.S. et al. and members of the PREMIER Group Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis. J Korean Med Sci 2011; 26 (1): 59–66.
  27. FDA Drug Safety Communication: Ongoing safety review of the angiotensin receptor blockers and cancer 2010.
  28. Bramlage P and Hasford J. Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany. Institutfür Medizinische Informations verarbeitung, Biometrie und Epidemiologie, University of Munich, Germany. Cardiovasc Diabetol 2009; 8: 18.
  29. Ferrario C.M., Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens (Greenwich) 2002; 4 (6): 424–32.
  30. Fogari R, Corradi I, Poletti L. et al. Sexual activity in hypertensive emales treated with valsartan or carvedilol. A cross - over study. J Hypertens 1999;17 (Suppl. 3): S65.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).